Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARG | Q86W56 | 4/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 5/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10146009 | 0.90 | P2RX3 (0.40) | PARGP2RX3GRM2GRIN1GRIN2B | |
| SCHEMBL625690 | 0.86 | GRM2 (0.43) | PARGP2RX3GRM2CRHR1CRHR2 | |
| SCHEMBL10145985 | 0.86 | GRIN1 (0.40) | PARGGRM2CRHR1CRHR2PPARG | |
| SCHEMBL625532 | 0.85 | NPC1 (0.40) | PARGGRM2CRHR1CRHR2PPARG | |
| SCHEMBL625527 | 0.85 | GRM2 (0.51) | PARGGRM2CRHR1CRHR2GRIN1 | |
| SCHEMBL624925 | 0.85 | GRM2 (0.46) | PARGP2RX3GRM2CRHR1CRHR2 | |
| SCHEMBL10145997 | 0.83 | PARG (0.42) | PARGGRM2CRHR1CRHR2GRIN1 | |
| SCHEMBL14992369 | 0.82 | PPARG (0.41) | PARGP2RX3GRM2CRHR1CRHR2 | |
| SCHEMBL10146338 | 0.82 | GRIN1 (0.48) | PARGGRM2CRHR1CRHR2GRIN1 | |
| SCHEMBL10146339 | 0.82 | PARG (0.43) | PARGGRM2CRHR1CRHR2GRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2603079-B1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | MERCK SHARP & DOHME (US) | 2018-09-19 | — | — | EP | claimed |
| US-8993779-B2 | Positive allosteric modulators of MGLUR2 | MERCK SHARP & DOHME CORP. (US) | 2015-03-31 | — | — | US | claimed |
| US-20130143880-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | MERCK SHARP & DOHME LLC | 2013-06-06 | — | — | US | claimed |
| EP-2603079-B1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | MERCK SHARP & DOHME (US) | 2018-09-19 | — | — | EP | disclosed |
| US-8993779-B2 | Positive allosteric modulators of MGLUR2 | MERCK SHARP & DOHME CORP. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993779-B2 | Positive allosteric modulators of MGLUR2 | MERCK SHARP & DOHME CORP. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993779-B2 | Positive allosteric modulators of MGLUR2 | MERCK SHARP & DOHME CORP. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20130143880-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | MERCK SHARP & DOHME LLC | 2013-06-06 | — | — | US | disclosed |
| US-20130143880-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | MERCK SHARP & DOHME LLC | 2013-06-06 | — | — | US | disclosed |
| US-20130143880-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | MERCK SHARP & DOHME LLC | 2013-06-06 | — | — | US | disclosed |
| WO-2012021382-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | MERCK SHARP & DOHME CORP. (US) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143880-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | GRM2, GRIA2, GRM1 | PARG 4723/4885P2RX3 338/4885GRM2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.